April 14, 2008 - Meda (STO:MEDAA) has acquired exclusive world-wide commercialisation rights from Orexo of two patented drugs in late development phase; Sublinox and OX-NLA. Sublinox (treatment of insomnia) contains the well-documented active substance zolpidem, one of the world’s most used substances for this disorder. Sublinox uses a unique and patented sublingual tablet formulation for fast and effective absorption. A recent phase III study confirmed that Sublinox gave faster onset of action than other zolpidem tablet formulations.
Regulatory submission to the Food and Drug Administration (FDA) in the United States is expected before the 3rd quarter 2008... [PDF] Meda's Press Release - Orexo's Press Release -
